Hepatitis C virus core antigen testing in liver and kidney transplant recipients
Standard
Hepatitis C virus core antigen testing in liver and kidney transplant recipients. / Heidrich, B; Pischke, S; Helfritz, F A; Mederacke, I; Kirschner, J; Schneider, J; Raupach, R; Jäckel, E; Barg-Hock, H; Lehner, F; Klempnauer, J; von Hahn, T; Cornberg, M; Manns, M P; Ciesek, S; Wedemeyer, H.
in: J VIRAL HEPATITIS, Jahrgang 21, Nr. 11, 01.11.2014, S. 769-779.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Hepatitis C virus core antigen testing in liver and kidney transplant recipients
AU - Heidrich, B
AU - Pischke, S
AU - Helfritz, F A
AU - Mederacke, I
AU - Kirschner, J
AU - Schneider, J
AU - Raupach, R
AU - Jäckel, E
AU - Barg-Hock, H
AU - Lehner, F
AU - Klempnauer, J
AU - von Hahn, T
AU - Cornberg, M
AU - Manns, M P
AU - Ciesek, S
AU - Wedemeyer, H
N1 - © 2013 John Wiley & Sons Ltd.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - HCV RNA levels correlate with the long-term outcome of hepatitis C in liver transplant recipients. Nucleic acid testing (NAT) is usually used to confirm HCV reinfection and to examine viral loads after liver transplantation. HCV core antigen (HCVcoreAg) testing could be an alternative to NAT with some potential advantages including very low intra- and interassay variabilities and lower costs. The performance of HCVcoreAg testing in organ transplant recipients is unknown. We prospectively studied 1011 sera for HCV RNA and HCVcoreAg in a routine real-world setting including 222 samples obtained from patients after liver or kidney transplantation. HCV RNA and HCVcoreAg test results showed a consistency of 98% with a very good correlation in transplanted patients (r > 0.85). The correlation between HCV RNA and HCVcoreAg was higher in sera with high viral loads and in samples from patients with low biochemical disease. Patients treated with tacrolimus showed a better correlation between both parameters than individuals receiving cyclosporine A. HCV RNA/HCVcoreAg ratios did not differ between transplanted and nontransplanted patients, and HCV RNA and HCVcoreAg kinetics were almost identical during the first days after liver transplantation. HCVcoreAg testing can be used to monitor HCV viral loads in patients after organ transplantation. However, the assay is not recommended to monitor antiviral therapies.
AB - HCV RNA levels correlate with the long-term outcome of hepatitis C in liver transplant recipients. Nucleic acid testing (NAT) is usually used to confirm HCV reinfection and to examine viral loads after liver transplantation. HCV core antigen (HCVcoreAg) testing could be an alternative to NAT with some potential advantages including very low intra- and interassay variabilities and lower costs. The performance of HCVcoreAg testing in organ transplant recipients is unknown. We prospectively studied 1011 sera for HCV RNA and HCVcoreAg in a routine real-world setting including 222 samples obtained from patients after liver or kidney transplantation. HCV RNA and HCVcoreAg test results showed a consistency of 98% with a very good correlation in transplanted patients (r > 0.85). The correlation between HCV RNA and HCVcoreAg was higher in sera with high viral loads and in samples from patients with low biochemical disease. Patients treated with tacrolimus showed a better correlation between both parameters than individuals receiving cyclosporine A. HCV RNA/HCVcoreAg ratios did not differ between transplanted and nontransplanted patients, and HCV RNA and HCVcoreAg kinetics were almost identical during the first days after liver transplantation. HCVcoreAg testing can be used to monitor HCV viral loads in patients after organ transplantation. However, the assay is not recommended to monitor antiviral therapies.
U2 - 10.1111/jvh.12204
DO - 10.1111/jvh.12204
M3 - SCORING: Journal article
C2 - 24251818
VL - 21
SP - 769
EP - 779
JO - J VIRAL HEPATITIS
JF - J VIRAL HEPATITIS
SN - 1352-0504
IS - 11
ER -
